Fifty 410 Review: There Is Nothing to Cancel — Which Is the Best Thing About It

What Is Fifty 410?

Fifty 410 is a direct-pay telehealth service selling compounded GLP-1 medication for weight loss. Its structure is unusually simple for this sector. There is no membership, no recurring subscription and no minimum commitment — the site's own words are "No membership, No Commitments...Ever." You complete a health assessment, a licensed provider reviews it within 24 to 48 hours, and if you are approved you pay for a course of medication. If you are not approved you do not pay at all.

The catalogue is narrow. Compounded tirzepatide and compounded semaglutide are the only weight-loss medications offered; there are no brand-name options. Tirzepatide at starter dosing is $133 a month or $399 for three months, and at high dose $183 a month or $549 for three months. The site also advertises hair-growth products and a longevity line — sermorelin, glutathione, NAD+ and methylene blue — as "coming soon," which are not available and which we have not assessed.

One inconsistency is worth raising early because it affects what a shopper expects to pay. The site advertises weight-loss medication as "Starting at $199/month" in one place while the tirzepatide product pricing begins at $133 a month in another. We could not reconcile the two figures, and we are reporting both rather than picking the flattering one. Treat the $199 as the number to budget against until the company clarifies, and check the total at checkout.

The medications are described accurately, which is more than several competitors manage: "compounded preparations containing FDA-approved active pharmaceutical ingredients, prepared by independent FDA-registered 503A and 503B compounding pharmacies," and explicitly "not FDA-approved finished drug products." That is the correct disclosure. What is missing is which pharmacies — a gap we return to below.

Medications Offered & Pricing

Prices checked on fifty410.com on 8 August 2026. The three-month bundles are the better value on a per-month basis — $399 across three months works out to $133 a month, matching the monthly rate rather than beating it, so the bundle buys convenience rather than a discount at starter dosing. Crucially, and unlike most providers in this series, there is nothing to add: no membership, no program fee, no consultation charge and no shipping cost. The $133 is the $133. That is the single strongest thing about this company's pricing, and it is undercut only by the unexplained "Starting at $199/month" figure elsewhere on the site.

Brand-Name or Compounded?

Fifty 410 sells compounded medication exclusively, and that is the central risk a reader needs to weigh — not because compounding is improper, but because the ground it stands on has moved.

The company's own disclosure is correct and we want to credit it: these are "compounded preparations containing FDA-approved active pharmaceutical ingredients" from "FDA-registered 503A and 503B compounding pharmacies," and they are "not FDA-approved finished drug products." Compounded drugs are not reviewed by the FDA for safety, effectiveness or manufacturing quality.

The regulatory position has tightened considerably. The FDA declared the tirzepatide shortage resolved in December 2024, and enforcement discretion ended on 18 February 2025 for 503A state-licensed pharmacies and 19 March 2025 for 503B outsourcing facilities. For semaglutide the shortage was declared resolved in February 2025, with the equivalent deadlines on 22 April and 22 May 2025. Then, in a notice published on 1 May 2026 with comments closing on 29 June 2026, the FDA proposed not to include semaglutide, tirzepatide or liraglutide on the 503B bulks list at all, having found no clinical need for outsourcing facilities to compound them from bulk substances.

Compounding a commercially available drug remains lawful under section 503A where the preparation is not essentially a copy of the approved product, which generally requires a documented clinical need for the individual patient — a different dose, or the removal of an ingredient they cannot tolerate. Fifty 410 offers distinct "starter" and "high dose" tiers, which is consistent with an individualised-dosing rationale, though the site does not set out that argument explicitly. We are not suggesting anything improper. We are saying that a compounded-only provider carries a supply risk that a provider offering brand-name alternatives does not, and Fifty 410 has no brand-name fallback if its pharmacy partners stop producing.

The pharmacies are not named, and that matters more here than at a provider with a mixed catalogue. Naming the facility would let you check whether it is a 503A pharmacy or a 503B outsourcing facility, look up its FDA inspection history, and see whether it has received a warning letter — the FDA issued several to GLP-1 compounders through 2025 and 2026. "FDA-registered" is also a weaker phrase than it sounds: registration is not approval, and it does not imply the agency has assessed the product.

There is a straightforward alternative worth knowing about, and Fifty 410 does not offer it. The FDA approved oral semaglutide as Wegovy tablets in December 2025, and approved Foundayo (orforglipron), Lilly's oral GLP-1, on 1 April 2026. Both are FDA-approved finished products. They cost more than $133 a month, and for many people that difference will be decisive — which is a legitimate reason to choose compounded. It is a different reason from believing the two are equivalent, and they are not.

The Consultation Process

Eligibility

• •BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related condition — the criteria named are type 2 diabetes, hypertension, high cholesterol, sleep apnea, cardiovascular disease and fatty liver disease.
• •Aged 18 or over.
• •Not pregnant.
• •No personal or family history of medullary thyroid carcinoma, and no multiple endocrine neoplasia syndrome type 2 — the standard contraindications carried on the approved GLP-1 labels.
• •Publishing these thresholds openly is a point in the company's favour; a number of providers we have reviewed leave eligibility vague or bury it in an FAQ.
• •State availability is described only as "most U.S. states," with no published list — you find out by entering your state in the assessment.

Provider Involvement, Labs & Pharmacy

Shipping & Support Services

The strongest operational disclosure on the site, and better than most. Orders ship overnight or 2-day and arrive refrigerated — "100% refrigerated throughout transit" with gel ice packs maintaining 36–46°F, which is the correct storage range for these medications. Shipping is free with no minimum purchase, and delivery is quoted at 2 to 4 business days from approval. Cold-chain detail at this level is genuinely uncommon in compounded GLP-1 telehealth and suggests the fulfilment side has been thought about.

• •Contact is by email, with refund requests handled through the same channel. We found no published customer telephone number, and no named clinical staff.
• •The refund process is documented with unusual precision: acknowledgement within 1 business day, review and approval in 2 to 3 business days, refund initiated within 5 business days, and funds received in 5 to 10 business days depending on payment method. There is an escalation route within 48 hours if you dispute a decision.
• •We found no Better Business Bureau profile, Trustpilot corpus or other independent complaint data for Fifty 410, which appears to be a relatively new entrant. That means we cannot tell you how it performs in practice — no complaints on file is not the same as a good record, it is an absence of evidence either way.
• •Because there is no subscription, the category of problem that dominates complaints against other providers in this series — being billed after cancelling — structurally cannot happen here.

Fees, Cancellation & Refunds

Insurance & HSA/FSA

Pros & Cons

Who Fifty 410 May Be Best For

• •People who want compounded GLP-1 medication without being enrolled in anything
• •Anyone who has been burned by a provider that kept billing after they tried to stop
• •Patients who want to try one month, or one three-month course, and then decide freely
• •Buyers paying with HSA or FSA funds, or who want to spread cost via Afterpay or Affirm
• •People who care about cold-chain handling and want a provider that documents it

Limitations

• •The compounded-only catalogue is the structural limitation. If you cannot tolerate the preparation, need a different molecule, or want to move to a brand-name product, Fifty 410 has nowhere to move you and you start again elsewhere. Providers with both compounded and branded lines can adjust without a change of company.
• •The clinical disclosure is thin. Unnamed providers, no published credentials, no statement about lab work, and no description of follow-up care. None of that means the care is poor — it means you cannot assess it before paying, which is a different problem but a real one.
• •The unresolved pricing discrepancy is the kind of detail that should not survive on a live commercial site. A prospective patient reading "Starting at $199/month" and a product page saying $133 has no way to know which applies to them.
• •No independent track record exists. There is no BBB profile and no meaningful third-party review corpus, so nothing external corroborates how the company behaves when something goes wrong. For a newer entrant that is expected, but it means the refund policy is a promise you are taking on trust.
• •Compounded GLP-1 supply now rests on the individualised-dosing argument rather than a shortage listing, and the FDA has proposed narrowing the 503B route further. A provider with no branded alternative is more exposed to that than one with a mixed catalogue.
• •The "coming soon" longevity line — sermorelin, NAD+, glutathione, methylene blue — is marketed on a page selling prescription weight-loss medication. Those products carry far weaker evidence than the GLP-1s do, and should not inherit their credibility.

Alternatives to Consider

Frequently Asked Questions

Our Verdict

Fifty 410 gets the commercial structure right in a category that almost universally gets it wrong, and that alone makes it worth a look.

There is no membership, no subscription, no minimum term and no consultation charge. The $133 tirzepatide price is the whole price — no programme fee, no shipping. Refunds are full and genuine right up until the medication is dispatched, including if a clinician disqualifies you, and the refund timeline is published step by step. Shipping is overnight or two-day, refrigerated, free. Eligibility criteria are stated openly rather than buried. And the answer to "how do I cancel" is that there is nothing to cancel. Across this whole series of reviews we have criticised non-refundable terms, hidden programme fees, and contracts that bind patients to months they cannot use. This company has simply not built any of that.

What holds it back is disclosure and range. It sells compounded medication only, at a moment when compounded GLP-1s rest on a narrower legal footing than at any point since 2023 — both shortages resolved, all four enforcement discretion deadlines passed in early 2025, and an FDA proposal in May 2026 to remove these drugs from the 503B bulks list. A compounded-only provider has no branded fallback if its pharmacy partners stop. And it will not tell you which pharmacies those are, who its clinicians are, whether any blood work is expected, or which states it serves.

The pricing discrepancy should be fixed. A site cannot advertise "Starting at $199/month" on one page and $133 on another and leave the customer to guess. We are reporting both figures because we could not establish which governs.

Rated 3.5 out of 5. If you know you want compounded tirzepatide, are comfortable that it is not an FDA-approved product, and value not being enrolled in anything, this is a well-designed way to buy it — and the absence of lock-in is worth real money against competitors charging a mandatory fee on top of the same headline price. If you want named clinicians, a lab baseline, a branded option, or a provider with a track record you can check, look elsewhere. Ask about labs and about your state before you pay, and make your decision before the medication ships, because that is the point after which the money is gone.